Lead Product(s): Avacopan
Therapeutic Area: Immunology Product Name: CCX168
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
ChemoCentryx plans to discuss the results with the U.S. Food and Drug Administration as it has obtained evidence of avacopan’s ability to improve renal function, being well-tolerated in C3G patients to date.